Abstract: Disclosed herein are embodiments of a compound useful for treating or preventing SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a SARS-CoV-2 infection in the subject. The compound may comprise an oligomer comprising a nucleic acid base sequence that is antisense to a gene, pre-mRNA or mRNA in the subject, such as a gene, pre-mRNA or mRNA of transmembrane serine protease 2 (TMPRSS2). The compound also may comprise a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).

Abstract: The invention provides the use of at least one binary group 15 element compound of the general formula R1R2E-E?R3R4 (I) or R5E(E?R6R7)2 (II) as the educt in a vapor deposition process. In this case, R1, R2, R3 and R4 are independently selected from the group consisting of H, an alkyl radical (C1-C10) and an aryl group, and E and E? are independently selected from the group consisting of N, P, As, Sb and Bi. This use excludes hydrazine and its derivatives. The binary group 15 element compounds according to the invention allow the realization of a reproducible production and/or deposition of multinary, homogeneous and ultrapure 13/15 semiconductors of a defined combination at relatively low process temperatures. This makes it possible to completely waive the use of an organically substituted nitrogen compound such as 1.

Abstract: The invention provides the use of at least one binary group 15 element compound of the general formula R1R2E-E?R3R4 (I) or R5E(E?R6R7)2 (II) as the educt in a vapor deposition process. In this case, R1, R2, R3 and R4 are independently selected from the group consisting of H, an alkyl radical (C1-C10) and an aryl group, and E and E? are independently selected from the group consisting of N, P, As, Sb and Bi. This use excludes hydrazine and its derivatives. The binary group 15 element compounds according to the invention allow the realization of a reproducible production and/or deposition of multinary, homogeneous and ultrapure 13/15 semiconductors of a defined combination at relatively low process temperatures. This makes it possible to completely waive the use of an organically substituted nitrogen compound such as 1.

Abstract: The invention at hand concerns hydrophobic polymer surfaces, in particular superhydrophobic polymer surfaces, comprising at least one homo- or copolymer, which comprises at least one side chain with at least one fluoro-substituted aryl group. Furthermore, the invention at hand concerns a method for the production of polymer surfaces of this type, their use and polymers of the general formula I: wherein n is an integer between 10 and 4,500, preferably between 20 and 2,200 and particularly preferably between 100 and 670.

Abstract: The invention relates to peptide mimetics comprising the residues P4-P3-P2-P1, which were cyclized between the side chains of P3 and P2 amino acid and are, as inhibitors of the serine protease plasmin, suitable to be used to inhibit fibrinolysis and thus to reduce blood loss in hyperfibrinolytic conditions, for example during surgery.

Abstract: The subject of the invention at hand are novel, a little basic, fluorinated pentafluorophenyl imide anions, which can be used as anions in ionic liquids. Methods for producing ionic liquids are described, which contain these novel pentafluorophenyl imide ions as anions, as well as quaternary organic ammonium ions, guanidinium ions, N-organo-pyridinium ions, imidazolium, imidazolidinium or benzimidazolidinium ions, alkyl-alkylidene phosphoranes or aryl-alkylidene phosphoranes as cations. Alternative methods according to the present invention provide ionic liquids through reaction of ketene N,N-diacetals or alkyl or aryl-alkylidene phosphoranes with acids. The ionic liquids according to the present invention are suitable, for example, as solvents for syntheses, as mobile and/or stationary phase in chromatography, as electrolyte systems for batteries, galvanic elements, fuel cells and rechargeable battery packs.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: The present invention provides a method to produce metal-containing nanoparticles enveloped with polymers, as well as particles obtainable therefrom. In the method according to the present invention, at least one anionic polymerizable monomer is polymerized in the presence of an anionic macroinitiator at room temperature. Subsequently, an aliphatic or aromatic sulfide is firstly added, followed by a solution of at least one organosoluble metal salt in an aprotic organic solvent and finally a homogeneous reducing agent. The metal cation is hereby reduced to the metal. Metal-containing nanoparticles are formed which are covalently bonded to the growing anionic polymerizates. The metal salts are preferably salts of silver, copper, gold, tin, lead, chrome or zinc, or mixtures thereof.

Abstract: The invention concerns an intraocular lens device which is used in particular for treatment of diseases of the central retina (macula) with retinal areas which are still healthy. The main principle of the invention at hand is that a lens device is provided for the redirection of the focal point from an area with impaired retinal function to a functioning area which comprises at least one convex lens element and several wedge-shaped recesses. Surprisingly it was found that a considerable reduction of the thickness of the lens device is thus achievable when several wedge-shaped recesses are provided.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: A method for the production of N-aryl carbamates (urethanes) and N-aryl isocyanates is described in which aromatic nitro compounds are subjected to a reductive carbonylation in the presence of carbon monoxide and organic compounds carrying hydroxyl groups, wherein the carbonylation is carried out in the presence of metal complex catalysts, for which anionic N,O chelate ligands of the general type [M(N˜O)?2] and [M(O˜N˜N˜O)2?] containing a bi- or trivalent transition metal of the groups 5 to 11 are used.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: The present invention provides a new procedure for the synthesis of CDNA from single cells after microdissection. It has the advantage that it is cost-efficient and can be carried out quickly with only few steps, even by less skilled laboratory employees. For the first time, the time-consuming and risky step of RNA isolation is omitted during cDNA synthesis from single cells by performing lysis and cDNA synthesis in the same reaction tube and in one buffer solution, which provides reliable and contamination-free results. The buffer is composed of NP40, carrier-RNA and Super RNAsin, as well as dNTPs and cDNA synthesis primers.